Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
Links shared publicly online about this topic.
- 1,862total visits
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
gsk.com —
not named
View full resource at gsk.com
Tags: Disease and Condition, GlaxoSmithKline
Most Recently Shared on July 29, 2009 at 1:45 pm By:
GSK withdraws Application in the EU for mepolizumab for treatment of hypereosinophilic syndrome http://bit.ly/QECWE
Advertisement
